Literature DB >> 8416307

Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia.

R B Cohen1, J M Abdallah, J R Gray, F Foss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8416307     DOI： 10.7326/0003-4819-118-2-199301150-00007

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  9 in total

Review 1.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 2.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 3.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.

Authors:  H I Tahsildar; B F Remler; R J Creger; B W Cooper; S M Snodgrass; R W Tarr; H M Lazarus
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

5.  Ocular toxicity of fludarabine: a purine analog.

Authors:  Xiaoyan Ding; Alexandra A Herzlich; Rachel Bishop; Jingsheng Tuo; Chi-Chao Chan
Journal:  Expert Rev Ophthalmol       Date:  2008-02

Review 6.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 7.  Oral fludarabine.

Authors:  Greg L Plosker; David P Figgitt
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 8.  A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Melissa Gabriel; Bianca A W Hoeben; Hilde Hylland Uhlving; Olga Zajac-Spychala; Anita Lawitschka; Dorine Bresters; Marianne Ifversen
Journal:  Front Pediatr       Date:  2021-12-23       Impact factor: 3.418

9.  Neurological illness following treatment with fludarabine.

Authors:  P W Johnson; J Fearnley; P Domizio; J Goldin; K Nagendran; J Gawler; A Z Rohatiner; T A Lister
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.